Table 2. Survival benefit of adjuvant treatment in breast cancer by PREDICT.

	Patient 1	Patient 2	Patient 3	Patient 4
Patient and tumor characteristics
Age	42	55	72	38
Mode of detection	Symptomatica	Screening	Symptomatic	Symptomatic
Tumor size (mm)	18	15	40	32
Tumor grade	3	2	2	3
Number of positive lymph nodes	3	0	2	1
Estrogen Receptor status	Negative	Positive	Positive	Negative
HER2 status	Positive	Negative	Negative	Negative
KI 67 status	Positive (>10%)	Unknown	Unknown	Positive (>10%)
Generation of chemotherapy regimen	Second	Third	Second	Third
5-Year survival results (%)
No adjuvant treatment	60	96	76	61
Benefit of adjuvant chemotherapy	15	1	3	18
Benefit of adjuvant Trastuzumab	6	n/a	n/a	n/a
Benefit of adjuvant hormone therapy	n/a	1	4	n/a
Total survival with adjuvant therapy	81	98	83	79
10-Year survival results (%)
No adjuvant treatment	49	90	50	49
Benefit of adjuvant chemotherapy	18	1	5	22
Benefit of adjuvant Trastuzumab	5	n/a	n/a	n/a
Benefit of adjuvant Hormone therapy	n/a	2	9	n/a
Total survival with adjuvant therapy	72	93	64	71

Abbreviations: HER2, human epidermal growth factor2.

^aPresented with palpable mass; data modified from PREDICT.^5,8